Singapore Eye Research Institute Tops Global Ophthalmology Rankings

Singapore Eye Research Institute Achieves Pinnacle in Ophthalmology Research Rankings 🌟

The Singapore Eye Research Institute (SERI), renowned for its pioneering work in ophthalmic and vision science, has secured the top spot in the prestigious ScholarGPS rankings for ophthalmology as of December 2025. This accolade positions SERI as number one among all non-academic institutes worldwide and a remarkable second place overall across all institutions globally. ScholarGPS, a comprehensive platform that evaluates scholarly performance, bases its assessments on research output, citation impact, and scholarly influence over the past five years. This triumph underscores Singapore's ascent as a global leader in medical research, particularly in addressing prevalent eye conditions affecting millions across Asia and beyond.

SERI's success is no accident but the culmination of nearly three decades of dedicated effort since its founding in 1997. As the research arm of the Singapore National Eye Centre (SNEC), SERI bridges clinical practice and cutting-edge science, translating discoveries into real-world treatments that prevent blindness and restore vision. With over 6,200 scientific publications, more than $489 million in competitive grants, 201 patents, and 885 national and international awards, SERI stands as the largest eye research institute in the Asia-Pacific region.

Understanding the ScholarGPS Rankings and SERI's Metrics

ScholarGPS stands out for its rigorous methodology, analyzing vast datasets from millions of scholars and thousands of institutions. It quantifies productivity through publication volume, gauges impact via citations from high-quality journals, and measures influence through collaborative networks and real-world applications. In ophthalmology—a field encompassing the study and treatment of eye disorders—SERI's metrics soared above competitors, reflecting consistent excellence in high-impact areas.

Compared to SCImago Institutions Rankings 2025, where SERI holds the 14th position in the health sector for ophthalmology (with SNEC at 9th), ScholarGPS highlights its edge in non-academic translational research. This dual recognition affirms SERI's prowess, especially vital as Asia grapples with rising myopia rates—projected to affect 2.5 billion people globally by 2050—and diabetic retinopathy, linked to Singapore's diabetes prevalence of nearly 10%.

Historical Journey: From Vision to Global Leadership

Conceived by the late Professor Arthur Lim amid Singapore's nascent research ecosystem, SERI began with just five staff members. Today, it boasts over 250 faculty, including clinician-scientists, PhD students, and adjunct professors from institutions like the National University of Singapore (NUS) Yong Loo Lin School of Medicine and Duke-NUS Medical School. This growth mirrors Singapore's Research, Innovation, and Enterprise (RIE) 2025 plan, which channels billions into biomedical sciences.

Key milestones include pioneering low-dose atropine for myopia control in the 1990s and contributing to bispecific antibody therapies. SERI's per capita publication rate in eye research surpasses giants like the US and UK, establishing Singapore as a hub where basic science swiftly becomes clinical reality.

Core Research Pillars Driving SERI's Success

SERI's portfolio spans multiple domains, each tackling Asia-specific challenges:

• Diabetic Retinopathy: Research elucidates vascular changes in the retina due to high blood sugar, developing screening algorithms using artificial intelligence (AI) for early detection—crucial as 1 in 9 Singaporeans has diabetes.
• Ocular Surface and Dry Eye Disease: Investigating tear film instability and inflammation, leading to novel therapies for chronic discomfort affecting office workers in humid climates.
• Cornea and Glaucoma: Step-by-step studies from genetic markers to surgical innovations, including endothelial cell therapies for corneal blindness.
• Myopia: Longitudinal cohorts track environmental and genetic factors, validating interventions amid Singapore's 80%+ myopia rate in young adults.
• Emerging Frontiers: AI-driven imaging, digital health platforms, and oculomics—using the eye as a window to systemic diseases like Alzheimer's.

These efforts yield actionable insights, such as AI models achieving 95% accuracy in diabetic retinopathy grading, deployable in community clinics.

Translational Breakthroughs: From Lab to Patient Bedside

SERI excels in the 'valley of death' between discovery and application. Vabysmo (faricimab), a decade-long collaboration with Roche, targets both VEGF and Ang-2 pathways in neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). This bispecific antibody extends treatment intervals from monthly to every 3-4 months, reducing patient burden and improving adherence—now approved globally, including in Asia.

Myopine, SERI's 0.01% atropine formulation, slows myopia progression by 50-60% in children with minimal side effects. Commercialized and available in Singapore, Malaysia, and beyond, it addresses the myopia epidemic driven by near-work and limited outdoor time. Long-term studies confirm safety over 20 years, with no increased risk of complications.

These successes stem from integrated processes: hypothesis generation via population studies like the Singapore Epidemiology of Eye Diseases (SEED), preclinical validation in SERI's labs, clinical trials at SNEC's facility, and regulatory approval through partnerships.

Strategic Collaborations Fueling Innovation

SERI's network amplifies impact. Domestically, the Centre for Vision Research with Duke-NUS integrates genetics and clinical data. Ties with NUS enable PhD training in AI-ophthalmology.

Internationally:

• Santen's SONIC 2.0 ($21M) targets glaucoma and myopia therapeutics.
• Carl Zeiss Meditec's OPTIZS ($20M) advances refractive and cataract surgery under RIE2025.
• Johnson & Johnson Vision's $36M myopia program develops next-gen drops and contacts.
• Stanford and global centers for retinal AI.

These alliances, supported by A*STAR and SingHealth Duke-NUS AMC, foster multi-disciplinary teams blending ophthalmology, data science, and engineering.

Spotlight on Top Researchers and Talent Pipeline

Leaders like Executive Director Professor Jodhbir S. Mehta, a corneal expert with global patents, and Professor Wong Tien Yin, AI ophthalmology pioneer, rank among the world's top scholars. Five SERI affiliates featured in recent highly cited lists, including A/Prof Daniel Ting for digital diagnostics.

SERI nurtures talent via PhD programs, Junior Overseas Scientist Fellowships, and adjunct roles. For higher education professionals eyeing Asia, Singapore offers vibrant opportunities in vision research. Explore research jobs or academic CV tips to join this ecosystem.

Implications for Singapore's Higher Education and Healthcare

This ranking bolsters Singapore's biomedical hub status, attracting talent to universities like NUS (SCImago #16 in ophthalmology). It enhances graduate training, with SERI's adjunct faculties mentoring PhDs who publish in top journals like Nature Medicine.

Healthcare-wise, SERI's work reduces economic burdens—myopia costs Asia $200B+ annually; early interventions via AI screenings save systems millions. Culturally, in a high-screen-time society, SERI promotes '20-20-2' rules: 20-second breaks every 20 minutes, outdoors 2 hours daily.

Challenges and Future Outlook

Despite triumphs, challenges persist: aging populations strain resources, needing scalable AI; ethical AI deployment requires bias audits. Funding competition intensifies globally.

Looking to 2026, SERI eyes gene therapies for inherited retinal diseases, advanced imaging for glaucoma progression, and oculomics for non-communicable diseases. With RIE2025 extensions, expect more spin-offs and trials. Professor Mehta notes: "We aim to translate research into better patient outcomes worldwide."

Career Opportunities in Singapore's Vision Research Boom

For academics and researchers, SERI's rise signals opportunities in postdocs, faculty roles, and industry partnerships. Singapore's ecosystem—stable funding, multicultural teams, English-medium—appeals globally. Check Singapore higher ed jobs, university positions, or postdoc openings. Aspiring clinician-scientists can leverage SERI fellowships for dual expertise.

In summary, SERI's ranking celebrates collective excellence, inviting the global community to collaborate on vision preservation. Stay informed via higher education news and engage with Rate My Professor for insights.

Photo by Galen Crout on Unsplash